Anabel Franco-Moreno , Pablo Ryan , Nuria Muñoz-Rivas , Jorge Valencia , Juan Torres-Macho , Susana Bacete-Cebrián
{"title":"跨性别人群接受激素治疗的静脉血栓栓塞风险：一项系统综述","authors":"Anabel Franco-Moreno , Pablo Ryan , Nuria Muñoz-Rivas , Jorge Valencia , Juan Torres-Macho , Susana Bacete-Cebrián","doi":"10.1016/j.medcle.2025.106921","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.</div></div><div><h3>Materials and method</h3><div>A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; <em>p</em> <!--><<!--> <!-->0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; <em>p</em> <!-->=<!--> <!-->0.60) were found.</div></div><div><h3>Conclusion</h3><div>Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 12","pages":"Article 106921"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of venous thromboembolism in the transgender population on hormone therapy: A systematic review\",\"authors\":\"Anabel Franco-Moreno , Pablo Ryan , Nuria Muñoz-Rivas , Jorge Valencia , Juan Torres-Macho , Susana Bacete-Cebrián\",\"doi\":\"10.1016/j.medcle.2025.106921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and objective</h3><div>Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.</div></div><div><h3>Materials and method</h3><div>A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; <em>p</em> <!--><<!--> <!-->0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; <em>p</em> <!-->=<!--> <!-->0.60) were found.</div></div><div><h3>Conclusion</h3><div>Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.</div></div>\",\"PeriodicalId\":74154,\"journal\":{\"name\":\"Medicina clinica (English ed.)\",\"volume\":\"164 12\",\"pages\":\"Article 106921\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina clinica (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2387020625002682\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625002682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Risk of venous thromboembolism in the transgender population on hormone therapy: A systematic review
Background and objective
Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.
Materials and method
A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.
Results
Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; p < 0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; p = 0.60) were found.
Conclusion
Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
